Insights from
UBC's Expert Voices

AI is everywhere in PV conversations, but far less mature in practice. Here's what stood out from Why Summit: Future of PV: validation bottlenecks, signal inflation, and why the real challenge isn't technology.

AI, standardization, and a shifting FDA landscape. Here's what the 2026 RIC Annual Meeting revealed about the future of REMS.

Canada's consent-driven data silos and the U.S.'s regulatory patchwork aren't just administrative hurdles — they're determinants of bias in real-world evidence.

Implementing Regulation (EU) 2025/1466 is in full effect — and it's the biggest change to EU pharmacovigilance rules in over a decade. Here's what your compliance team needs to act on right now.

Two phrases defined this year's Access USA conference: "calm the chaos" and "can't eliminate the human touch." As AI reshapes patient support programs, the question isn't whether to adopt it, but how to deploy it without losing what patients value most.

Women's depression is often framed as a hormonal imbalance of the body. Men's? A failure of will. These aren't just outdated ideas — they're active barriers to diagnosis, treatment, and survival. As treatment-resistant depression challenges conventional medicine, psychedelic-assisted therapy is emerging not only as a clinical option, but as a way to dismantle the very stigmas that keep people from seeking help in the first place.

As psychedelics move toward potential FDA approval, Oregon’s psilocybin service centers offer early lessons in patient-centered care. This article examines real-world practices in preparation, dosing, facilitation, and integration—and what they may reveal about future clinical use.

Immune checkpoint inhibitors deliver transformative outcomes, yet real‑world durability is often limited by primary and acquired resistance. This article explores the biological foundations of ICI resistance and outlines how integrating these insights into HEOR models can improve value assessment and real‑world decision‑making.

As AI becomes embedded across pharmacovigilance, the skills required of safety scientists are rapidly evolving. This article examines the shifting balance between human expertise and AI-enabled tools, outlining the competencies, training pathways, and cultural changes needed to prepare tomorrow’s hybrid PV workforce.